Riset dan Pengabdian Masyarakat
Do Research Sosial Service and Innovation
Publikasi Scopus 926 artikel (Per 14 Maret 2022)
Publikasi Scopus 926 artikel (Per 14 Maret 2022)
The potential of gallic acid as a radiosensitizer on human prostate cancer: A systematic review of preclinical studies
2021
Malaysian Journal of Medicine and Health Sciences
17
2
246
254
https://www.scopus.com/inward/record.uri?eid=2-s2.0-85104201486&partnerID=40&md5=aff7e4b57216dc4b88ee83f02823372e
Department of Radiation Oncology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia; Department of Pharmacology and Therapeutics, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Integrated Laboratory, Faculty of Medicine, Universitas Indonesia, Jakarta, Indonesia; Department of Urology, Faculty of Medicine, Universitas Indonesia-Cipto Mangunkusumo Hospital, Jakarta, Indonesia
Prostate adenocarcinoma accounts for majority of prostate cancer cases, and it was found to be highly radioresistant. Gallic acid is a phenolic acid naturally occurring in many plants, reported to exhibit biological activities in eliminating cancer cell lines and xenografts. The purpose of this study is to review gallic acid as a potential radiosensitizer agent in prostate cancer treatment. Article search was conducted in PubMed, EBSCO, and Scopus. 11 studies using different cell lines including DU145, PC-3, LNCaP, and 22Rv1 xenograft of human prostate cancer were reviewed in this paper. Gallic acid acts as a radiosensitizer mainly by increasing caspase-3 and caspase-9 activation resulting in apoptosis, while also reducing intracellular CDKs, cyclins, and cdc25 phosphatases ultimately causing G2-M cell cycle arrest. Gallic acid has a potential to be a new radiosensitizer compound in prostate cancer treatment. Additional clinical studies using gallic acid derivatives with lower hydrophilicity are needed. © 2021 UPM Press. All rights reserved.
Universiti Putra Malaysia Press
16758544
Review
Q4
144
23823